ABIN362261
antibody from antibodies-online
Targeting: MTOR
FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN362261 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Mechanistic Target of Rapamycin (serine/threonine Kinase) (FRAP1) (pSer2448) antibody
- Antibody type
- Polyclonal
- Antigen
- Peptide sequence around phosphorylation site of pSer2448 (T-D-S (p) -Y-S) derived from Human mTOR. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.
- Description
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography usingepitope-specific phosphopeptide. The antibody against non-phosphopeptide was removedby chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- pSer2448
- Isotype
- IgG
- Vial size
- 50 μL
- Concentration
- 1 mg/mL
- Storage
- Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.
Submitted references Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment.
5-Aza-2'-deoxycytidine inhibited PDGF-induced rat airway smooth muscle cell phenotypic switching.
mTOR signalling in human cancer.
Macias M, Blazejczyk M, Kazmierska P, Caban B, Skalecka A, Tarkowski B, Rodo A, Konopacki J, Jaworski J
PloS one 2013;8(5):e64455
PloS one 2013;8(5):e64455
5-Aza-2'-deoxycytidine inhibited PDGF-induced rat airway smooth muscle cell phenotypic switching.
Ning Y, Huang H, Dong Y, Sun Q, Zhang W, Xu W, Li Q
Archives of toxicology 2013 May;87(5):871-81
Archives of toxicology 2013 May;87(5):871-81
mTOR signalling in human cancer.
Albanell J, Dalmases A, Rovira A, Rojo F
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007 Aug;9(8):484-93
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007 Aug;9(8):484-93
No comments: Submit comment
No validations: Submit validation data